Skip to main content

Balyasny Asset Management — Portfolio

Investor actively backing innovative startups and growth-stage companies across various industries and funding rounds.

42
Companies
$4.4B
Total invested
$100.4M
Avg. check
26
Industries
Biotechnology 19Health Care 13Therapeutics 10Biopharma 7Pharmaceutical 7Life Science 5+20 more
Founder contacts

Verified emails & LinkedIn for founders across this portfolio.

jane@on●●●●●●●.com
linkedin.com/in/●●●●●●
Verified contacts, updated monthly
Get instant access →

Portfolio companies

Showing 1–24 of 42
Expedition Therapeutics
August 2026

Expedition Therapeutics develops treatments for COPD and other inflammatory respiratory diseases.

Biotechnology · San Francisco$115.0M Series B
Avant
July 2026

Avant is an online lending platform that offers alternatives to its clients with safe financial products.

Consumer Lending · Chicago$300.0M Debt Financing
LB Pharmaceuticals
July 2026

LB Pharmaceuticals specializes in developing LB-102 (n-Methyl amisulpride) as a treatment for schizophrenia.

Biopharma · New York$150.0M Post-IPO Equity
Jasper Therapeutics
July 2026

Jasper Therapeutics is a biotechnology company that develops novel antibody therapies for stem cell transplants.

Biotechnology · Redwood City$132.0M Post-IPO Equity
Tango Therapeutics
June 2026

Tango Therapeutics is a biotechnology company that is developing next generation cancer therapies.

Biotechnology · Cambridge$600.0M Post-IPO Equity
Lycia Therapeutics
June 2026

Lycia Therapeutics is a biotechnology company that focuses on developing technology that utilizes lysosome-targeting chimeras.

Biotechnology · South San Francisco$75.0M Series D
Bright Machines
June 2024

Bright Machines brings together flexible factory robots with intelligent software, production data and machine learning.

Computer · San Francisco$106.0M Series C
Oak hill bio
June 2026

Oak hill bio is a clinical-stage rare disease therapeutics company developing life-changing medicines.

Biotechnology · Altrincham$32.5M Series A
Quince Therapeutics
May 2026

Quince Therapeutics is developing treatments for Alzheimer's and other degenerative disorders.

Biotechnology · South San Francisco$115.0M Post-IPO Equity
Opus Genetics(formerly Ocuphire Pharma)
April 2026

Opus Genetics a clinical-stage biopharmaceutical company, develops and commercializes therapies for patients with ophthalmic disorders.

Biopharma · Farmington Hills$35.0M Post-IPO Debt
Coultreon Biopharma
April 2026

CoultreonBiopharma is developing best-in-class therapeutics that target clinically validated pathways in immunology and metabolic illnesses.

Analytics · Heverlee$125.0M Series A
RapidSOS
April 2026

RapidSOS is an intelligent safety platform that connects devices, apps, and sensors for safety agents.

Artificial Intelligence (AI) · New YorkUndisclosed
Korro Bio
March 2026

Korro Bio provides an efficient and selective method for RNA editing, leveraging natural processes common to all multi-cellular organisms.

Biotechnology · Cambridge$85.0M Post-IPO Equity
Acorns
March 2022

Acorns is a financial technology and services company that specializes in automated investments and robo-advice.

Finance · Irvine$300.0M Series F
Activ Surgical
March 2022

Activ Surgical is a digital surgery company focused on improving surgical efficiency, accuracy, patient outcomes, and accessibility.

Artificial Intelligence (AI) · Boston$15.0M Series B
Ovid Therapeutics
March 2026

Ovid Therapeutic's purpose is to solve intractable medical problems.

Biopharma · New York$60.0M Post-IPO Equity
Galecto
February 2026

Galecto is a clinical stage biotechnology company focused on the development of novel treatments for fibrosis and cancer.

Biotechnology · Copenhagen$275.0M Post-IPO Equity
Crescent Biopharma
December 2025

Crescent Biopharma is a biotechnology firm focused on developing novel precision-engineered medicines.

Biotechnology · Rockville$185.0M Post-IPO Equity
CAMP4 Therapeutics
December 2025

CAMP4 Therapeutics is a biotechnology company that uses RNA to restore healthy gene expression.

Biopharma · Cambridge$30.0M Post-IPO Equity
Ambros Therapeutics
December 2025

Ambros Therapeutics is a clinical-stage biotechnology company.

Biotechnology · Irvine$125.0M Series A
LEXEO Therapeutics
October 2025

LEXEO Therapeutics utilizes gene therapy to treat genetically defined cardiovascular and central nervous system diseases.

Biotechnology · New York$154.0M Post-IPO Equity
Adlai Nortye
February 2026

Adlai Nortye is a clinical-stage biopharmaceutical company that deveops cancer treatments for diverse tumor types.

Biotechnology · Hangzhou$140.0M Post Ipo Equity
TRex Bio
January 2026

TRex Bio is a biotechnology company that treats diseases like cancer, fibrotic by studying human tissues.

Bioinformatics · South San Francisco$50.0M Series Unknown
Diagonal Therapeutics
January 2026

Diagonal Therapeutics is a biotechnology startup that develops targeted therapies for cancer and genetic diseases.

Biopharma · Watertown$125.0M Series B

Where Balyasny Asset Management invests

Biotechnology19
Health Care13
Therapeutics10
Biopharma7
Pharmaceutical7
Life Science5

About Balyasny Asset Management's portfolio

How many companies has Balyasny Asset Management invested in?▸

Balyasny Asset Management has invested in 42 companies tracked in our database. The portfolio spans multiple industries and funding stages, from seed-stage startups to late-stage companies.

What industries does Balyasny Asset Management invest in?▸

Balyasny Asset Management's top investment sectors include Biotechnology, Health Care, Therapeutics, Biopharma, Pharmaceutical. The firm invests across 26 different industry categories.

What is Balyasny Asset Management's largest investment?▸

Among tracked funding rounds, Tango Therapeutics received $600.0M in a Post-IPO Equity round. Balyasny Asset Management's total known invested capital is $4.4B.

What is the average investment size for Balyasny Asset Management?▸

Balyasny Asset Management's average investment size is $100.4M across its portfolio of 42 companies.

What are Balyasny Asset Management's most recent investments?▸

Recent Balyasny Asset Management portfolio additions include Expedition Therapeutics, Avant, LB Pharmaceuticals, Jasper Therapeutics, Tango Therapeutics. These companies were founded in 2020 or later.

Reach the founders behind these 42 companies
Verified emails and LinkedIn profiles, updated monthly.
Get instant access →